Speratum Biopharma, Inc.
June 16, 2025
Company Presentation
Oncology
Speratum Biopharma is pioneering the future of precision oncology with cutting-edge miRNA-based therapeutics. Our lead program, NM-198, leverages our proprietary Nano-In™ and NoPass™ delivery platforms to target solid tumors with unprecedented specificity and efficacy. Rooted in innovation, Speratum is advancing a robust pipeline of transformative cancer therapies designed to overcome resistance and enhance patient outcomes. With a dedicated team of scientists and industry leaders, we are committed to redefining the landscape of oncology treatment.
Company HQ City:
Dover
Company HQ State:
DE
Company HQ Country:
United States
Year Founded:
2014
Lead Product in Development:
NM-198
CEO
Christian Marin-Muller, M.S., PhD
Year Founded
2014
Development Phase of Lead Product
Pre-Clinical
Number of Unlicensed Products Looking for Licensing
1) NM-198
2) NM-520
3) NM-V1
When you expect your next catalyst update?
Q2 2025
What is your next catalyst (value inflection) update?
June 2025
Website
https://www.speratum.com
Primary Speaker
)
)
)
)
){kind=logo}
)
){kind=logo}
)
){kind=logo}